Vocation for caring and the capacity to generate value
Annual Report 2020

Highlights of 2020 GRI 102-7

Governance GRI 102-7

Net Revenue of
R$ 3,5 billion
EBITDA of
R$ 1,0 billion, with a
margin of 30.1%
Net Income of
R$ 631.4 million and
Earnings per Share of R$ 9.9
in the year
R$2.3 billion of added
value distributed
Net leverage of
0.59x EBITDA
AAA rating with a stable
outlook from Fitch and
Standard & Poor’s

The Environment GRI 102-7

R$ 4,4 million invested in
environmental initiatives
25% reduction in the
consumption of electricity
used for producing cold water
44% increase in the
volume of recycled water
Reforestation of
4,5 hectares (45,000 m2)
in Suape - PE
11,2% reduction in total
energy consumption compared to
2019 at the Guarulhos and São Paulo plants
45,7% reduction in the number
of tons of paper used in promotional
material compared to 2019
262 million cartridges, and 269
million package inserts for drugs made from
reforestation wood, certified by the
Forest Stewardship Council (FSC)

Social GRI 102-7

R$ 14,8 million invested in
social programs, contributing to 21 projects,
considering direct resources
and tax incentive laws
R$ 6,5 million donated to
combating Covid-19
R$ 31,5 million invested in
employees development
15,9 million people registered
in the Care for Life
Benefits Program
5.119 employees
2.710 professionals working
in the Commercial Sales
and Demand Forces
565 hours of training
44% staff moved internally
(job positions filled by our
Strategic plan 2020-2025

Leader in prescription drugs

• Leading laboratory for demand in the medically prescribed drugs segmento

• Lupa de Ouro Award in the categories: Adalmiro Baptista Marketing Excellence – Best Corporate Performance (Digital); and Sales Force Excellence – Best Work in Digital Marketing

Innovation agility

• 46 new products launched

• 173 projects in the pipeline

• R$ 104 million (10% of EBTIDA) invested in Innovation

• Valor Inovação [Valor Innovation]:

1st in the Pharmaceutical & Life Sciences sector

Preferred by our customers

• Reclame AQUI Award: Champion in the Chemical & Pharmaceutical category

• Global Pharma Study Caliber: Aché was recognized as the pharmaceutical company with the best reputation in its market

Execution excellence

• 218 million units produced in the 5 plants

• R$ 29 million invested in operational excellence projects

• R$ 100.5 million invested in setting up a new manufacturing plant and a modern vertical warehouse in Cabo de Santo Agostinho - Pernambuco

• 57.4% in overall equipment effectiveness (OEE)